



- THE TRUSTED CLINICAL TRIALS BUSINESS RESOURCE

CAL TRIALS

Magazine Blogs Learning Video Advertise Contact Us

CRO/Sponsor ClinTech

Project Managers Labs

Regulatory

RBM

Sites

Trial Design Events

Achieving End-to-End Traceability

Using Trace-XML

Jan 12, 2017 By Samuel Hume

esults, traceability plays a crucial role in reinforcing clinical research analysis PMDA). Because a study's strength hinges on the integrity of source data as well as the quality and reproducibility of the processes used to generate the equirement for studies submitted to the US Food and Drug Administration content of a submission database can explicitly trace back to the original FDA) and the Japanese Pharmaceuticals and Medical Devices Agency esults. In regulatory submissions, sponsors must demonstrate that the Traceability is an essential element of data quality and a regulatory source data in an unbroken chain, including any transformations or derivations that may have altered the data.

datasets created for use in clinical research. Define-XML is required as part of The Clinical Data Interchange Standards Consortium (CDISC) has developed epresent metadata for data artifacts, such as case report forms (CRFs) and the models, Operational Data Model (ODM-XML) and Define-XML, to

Enter your Keyword or Phra Search

This Site

Include Affiliate Sites



Subscribe now to Applied Clinical Trials





a standards-compliant, regulatory submission to the FDA and PMDA and plays a key role in establishing traceability for submission datasets. Define-XML 2.0 provides most of the metadata needed to enable software traceability. Specifically, it provides descriptive metadata that displays the previous step in the clinical research data lifecycle. However, it does not provide the explicit references to source variables that would enable computable end-to-end traceability. Without these source variable references, automated end-to-end validation and traceability queries are not possible.

Trace-XML is a new extension to Define-XML v2.0, which delivers end-to-end, clinical data lifecycle traceability from data collection through final analysis.

The Trace-XML extension enables standardized clinical study metadata to be represented as a graph, displaying the complete history of each data element to facilitate assessing audit trail completeness and correctness. The metadata supplied by Define-XML v2.0 and ODM-XML v1.3.2 includes the variables, datasets, sub-forms, forms, and computational methods that become the nodes in the graph representation of the study metadata.





Figure 1. Conceptual example showing the type of Trace-XML content created for a variable trace.

Trace-XML adds the metadata needed to connect a variable, represented as



TRIALS REQUIRE PRECISE EXECUT COMPLEX IMMUNO-ONCOLOGY

(API), or from SHARE exports. Source variables and connecting edges generated by the Trace-XML software are derived directly from CDISC standards, enabling it to graphically illustrate how these standards are interconnected based on variables used across different standards and in different versions of those standards. Once the graph representation of the study metadata has been created, an analysis variable can be traced back to its source providing traceability across a full study. For reviewers, Trace-XML



Webcasts

Operational Challenges in Resourcing and Executing Seasonal Infectious Diseases Studies

allows end-to-end querying, validation, and visualization of metadata across the data lifecycle. Traces generated by Trace-XML can be referenced in Define-XML to package full lifecycle traceability in a regulatory submission. Moreover, Trace-XML can broaden the concept of end-to-end by beginning with eSource data (electronic healthcare records) and flowing through to analysis results.

The Trace-XML end-to-end traceability improvements complement the existing ODM-XML audit trail and Define-XML traceability features to provide an enhanced CDISC provenance capability. CDISC will make Trace-XML (the software and Define-XML extension) freely available on our web site in early 2017.

Sam Hume, Head of Data Exchange Technologies, CDISC

Add new comment

Refocusing on Risk Wittigation in Starting Clinical Trik

Challenges in Biosim Assays and Sample F

White Papers

From six months to three weeks: How a leading CRO accelerated research results with Proscia's digital pathology platform

Revised Common Rule Quick Reference

By Advarra

Protecting Sponsors Against Bias and Variability